Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$120.89 USD

120.89
902,634

+0.47 (0.39%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $120.83 -0.06 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug

by Zacks Equity Research

Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).

    Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon

    by Zacks Equity Research

    Novartis' (NVS) fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. The company has been facing challenging conditions for the past few quarters.

      Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

      by Zacks Equity Research

      Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

        Novartis to Conduct Trial on Obese, Type II Diabetes Patients

        by Zacks Equity Research

        In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.

          ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

          by Zacks Equity Research

          On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

            Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

            by Zacks Equity Research

            Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.

              Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments

              by Zacks Equity Research

              Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.

                Teva Falls on Disappointing 2017 Sales & Earnings Guidance

                by Zacks Equity Research

                Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.

                  Momenta (MNTA) to Receive $50M Under CSL Collaboration

                  by Zacks Equity Research

                  Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.

                    Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication

                    by Zacks Equity Research

                    Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.

                      Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit

                      by Zacks Equity Research

                      Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.

                        Incyte Treats First Patient in Phase II GVHD Study on Jakafi

                        by Zacks Equity Research

                        Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.

                          ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong

                          by Zacks Equity Research

                          Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.

                            Ligand (LGND) Signs Licensing Deals with Ono and Novartis

                            by Zacks Equity Research

                            Ligand Pharmaceuticals announced that it has entered into a worldwide license agreement with Ono Pharmaceutical under which Ono will use its OmniAb platform for the discovery of fully human mono- and bispecific antibodies.

                              Pfizer Ibrance sNDA Accepted by FDA under Priority Review

                              by Zacks Equity Research

                              Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

                                Conatus Stock Up on Liver Drug Collaboration with Novartis

                                by Zacks Equity Research

                                Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.

                                  Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

                                  by Zacks Equity Research

                                  Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

                                    Ophthotech Hits 52-Week Low on Unfavorable Fovista Data

                                    by Zacks Equity Research

                                    Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.

                                      Novartis Offers Positive Data on Breast Cancer Drug LEE011

                                      by Zacks Equity Research

                                      Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.

                                        Teva Copaxone EU Label to Omit Pregnancy Contraindication

                                        by Zacks Equity Research

                                        Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.

                                          Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

                                          by Zacks Equity Research

                                          Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

                                            Incyte Jakafi Positive in Pooled Analysis of Five-Year Data

                                            by Zacks Equity Research

                                            Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.

                                              ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

                                              by Zacks Equity Research

                                              ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

                                                Company News for November 22, 2016

                                                by Zacks Equity Research

                                                Companies In The News: TSN,FB,NVS,LOCK,SYMC